On the evening of March 29, 2026, Insilico Medicine disclosed its annual financial results for 2025. The financial report revealed that the company's total revenue for the year soared to USD 56.24 million. Moreover, it achieved a significant milestone by successfully listing on the main board of the Hong Kong Stock Exchange on December 30, 2025, garnering widespread acclaim and support from investors worldwide. By December 31, 2025, the company's cumulative bank balance and cash reserves had reached a substantial USD 393 million.

Insilico Medicine has consistently enhanced its Pharma.AI platform, with its software platform now serving 13 out of the top 20 global pharmaceutical companies. The revenue generated from its software business witnessed a remarkable 23.8% year-on-year growth in 2025. Leveraging the power of its AI platform, the company successfully identified six preclinical drug candidates and propelled eight projects into clinical development stages.

Guided by its "AI + Drug Discovery" dual-engine strategy, Insilico Medicine forged over 10 new partnerships, collectively valued at USD 1.3 billion. Several projects under this strategy have reached pivotal milestones. Looking ahead, Insilico Medicine is set to concentrate on refining its Pharma.AI platform to further boost R&D efficiency and success rates, diversify its product offerings, and expand its collaborative network. The company has scheduled an online earnings report meeting for March 30, 2026.